利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.025 秒)

    FENOFIBRATE FORMULATION WITH ENHANCED ORAL BIOAVAILABILITY
    1.
    发明申请
    FENOFIBRATE FORMULATION WITH ENHANCED ORAL BIOAVAILABILITY 审中-公开
    具有增强口腔生物利用度的FENOFIBRATE配方

    公开(公告)号：US20110160274A1

    公开(公告)日：2011-06-30

    申请号：US13002372

    申请日：2009-06-26

    申请人： Rajesh Jain ,  Sarabjit Singh ,  Naveen Jain ,  Shivanand Puthli

    发明人： Rajesh Jain ,  Sarabjit Singh ,  Naveen Jain ,  Shivanand Puthli

    IPC分类号： A61K31/40 ,  A61K31/216 ,  A61P3/10 ,  A61P9/00

    CPC分类号： A61K9/4858

    摘要： The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions such as hypertriglyceridemia, hypercholesterolemia and mixed dyslipidemia, and can also be effective at lower doses as compared to commercially available products. The invention additionally relates to the process of manufacture of the formulation and to dosage forms comprising the same.

    摘要翻译： 本发明提供了非诺贝特配方，其具有增强的口服生物利用度，设计和制造的简单性和食物效果的不存在。 该制剂包含溶解在亲脂性表面活性剂中的非诺贝特，任选加入亲水性表面活性剂。 该制剂可以有效地用于治疗和治疗诸如高甘油三酯血症，高胆固醇血症和混合性血脂异常之类的病症，并且与可商购的产品相比也可以以较低的剂量有效。 本发明还涉及制剂的制备方法和包含其的剂型。

    MODIFIED DOSAGE FORMS OF TACROLIMUS
    2.
    发明申请
    MODIFIED DOSAGE FORMS OF TACROLIMUS 审中-公开
    改良剂量剂型

    公开(公告)号：US20100086592A1

    公开(公告)日：2010-04-08

    申请号：US12530011

    申请日：2008-03-25

    申请人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli ,  Rajesh Jain

    发明人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli ,  Rajesh Jain

    IPC分类号： A61K9/24 ,  A61K31/436 ,  A61K9/16

    CPC分类号： A61K9/146 ,  A61K9/1676 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/436

    摘要： The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described.

    摘要翻译： 本发明提供了他克莫司的释放剂量形式，其口服给药释放两种或更多量的他克莫司，第一批量的他克莫司基本上立即在0-2小时内立即从即时释放剂量单位释放，之后是从约 1-10小时，其中基本上没有量的他克莫司从剂型中释放出来，之后第二量的他克莫司被释放，其中所述第二量从延迟释放剂量单位释放， 在0-2小时内或超过延迟释放剂量单位从其初始释放约2-12小时的时间段内。 剂型还可包含额外量的他克莫司以提供他克莫司的额外脉冲。 他克莫司的剂型表现出改善的生物利用度和减少通量或波动超过现有组合的他克莫司。 还描述了制备剂型的方法。

    SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN
    3.
    发明申请
    SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN 审中-公开
    持续发布包含PREGABALIN的药物组合物

    公开(公告)号：US20130280324A1

    公开(公告)日：2013-10-24

    申请号：US13824188

    申请日：2011-09-15

    申请人： Rajesh Jain ,  Sarabjit Singh ,  Shivanand Puthli

    发明人： Rajesh Jain ,  Sarabjit Singh ,  Shivanand Puthli

    IPC分类号： A61K9/00 ,  A61K47/26 ,  A61K31/197

    CPC分类号： A61K9/0002 ,  A61K9/1623 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/197 ,  A61K47/26

    摘要： The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.

    摘要翻译： 本发明涉及稳定的每日一次的持续释放药物组合物，其包含普瑞巴林或其药学上可接受的盐和药学上可接受的赋形剂，其中药物组合物与普通巴布林常规立即释放制剂每天两次生物等效。 本发明还涉及一种组合物，其包含普瑞巴林和糖酯作为用于保持药物的均匀释放速率的释放阻滞剂和用于制备这种口服持续释放制剂的方法。

    Programmable buoyant delivery technology
    4.
    发明授权
    Programmable buoyant delivery technology 有权
    可编程浮力输送技术

    公开(公告)号：US08277843B2

    公开(公告)日：2012-10-02

    申请号：US12439775

    申请日：2007-09-03

    申请人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli ,  Rajendra Tandale

    发明人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli ,  Rajendra Tandale

    IPC分类号： A61K9/24

    CPC分类号： A61K9/0065 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2095 ,  A61K9/2886

    摘要： The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.

    摘要翻译： 本发明涉及用于活性剂的空间和时间可编程递送的系统。 口服给药时，可以将系统长时间保留在胃区。 它包括芯（I），涂覆在芯上的一层或多层（II，IV，V）和预成形的中空空间（III）。 本发明还涉及用于制备该系统的方法和一种治疗/预防疾病的方法，通过向有需要的受试者施用本发明的系统。

    TRANSMUCOSAL COMPOSITION
    6.
    发明申请
    TRANSMUCOSAL COMPOSITION 审中-公开
    转运组合物

    公开(公告)号：US20090110717A1

    公开(公告)日：2009-04-30

    申请号：US12297486

    申请日：2007-04-25

    申请人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli

    发明人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli

    IPC分类号： A61K9/70 ,  A61K9/00 ,  A61K39/00 ,  A61K31/4178 ,  A61K31/4045 ,  A61K31/445 ,  A61K31/4375

    CPC分类号： A61K9/0056 ,  A61K9/006 ,  A61K9/2072 ,  A61K9/2086

    摘要： The invention provides a composition for delivering active agents through transmucosal administration, more particularly through the buccal mucosa. The composition is a unique transmucosal disk (10) which has two compartments (14) and (18); the compartments consist of at least one active agent and at least one mucoadhesive agent and both the compartments are adapted to be in contact with the mucosal membrane. The invention also provides for transmucosal administration of an active agent and method of treatment of diseases in a subject in need of such treatment.

    摘要翻译： 本发明提供了一种用于通过经粘膜给药递送活性剂的组合物，更具体地通过颊粘膜递送。 该组合物是独特的经粘膜盘（10），其具有两个隔间（14）和（18）; 隔室由至少一种活性剂和至少一种粘膜粘附剂组成，并且两个隔室都适于与粘膜接触。 本发明还提供活性剂的经粘膜给药和治疗需要这种治疗的受试者的疾病的方法。

    METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS
    7.
    发明申请
    METHODS AND COMPOSITIONS FOR PRODUCING ANTI-ANDROGENIC EFFECTS 审中-公开
    用于生产抗坏血酸作用的方法和组合物

    公开(公告)号：US20090317464A1

    公开(公告)日：2009-12-24

    申请号：US12305025

    申请日：2007-07-05

    申请人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli

    发明人： Amarjit Singh ,  Sarabjit Singh ,  Shivanand Puthli

    IPC分类号： A61K9/24 ,  A61K31/167 ,  A61K9/20 ,  A61P5/28

    CPC分类号： A61K31/10 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2886 ,  A61K31/167

    摘要： The invention provides a method and a composition for producing an anti-androgenic effect in a mammal. The method comprises administering a modified release pharmaceutical composition of bicalutamide to a mammal, with a reduced dosing frequency, for improved patient convenience and compliance. The composition of the invention also provides for a higher bioavailability and improved pharmacokinetic profile as compared to a conventional bicalutamide composition.

    摘要翻译： 本发明提供了一种用于在哺乳动物中产生抗雄激素作用的方法和组合物。 该方法包括向哺乳动物施用改性释放的药物组合物，其具有降低的给药频率，以改善患者的便利性和依从性。 与常规比卡鲁胺组合物相比，本发明的组合物还提供更高的生物利用度和改善的药代动力学特征。